CA2727022A1 - Rasagiline for parkinson's disease modification - Google Patents
Rasagiline for parkinson's disease modification Download PDFInfo
- Publication number
- CA2727022A1 CA2727022A1 CA2727022A CA2727022A CA2727022A1 CA 2727022 A1 CA2727022 A1 CA 2727022A1 CA 2727022 A CA2727022 A CA 2727022A CA 2727022 A CA2727022 A CA 2727022A CA 2727022 A1 CA2727022 A1 CA 2727022A1
- Authority
- CA
- Canada
- Prior art keywords
- rasagiline
- patient
- parkinson
- disease
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title claims abstract description 397
- 229960000245 rasagiline Drugs 0.000 title claims abstract description 394
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 263
- 230000004048 modification Effects 0.000 title description 3
- 238000012986 modification Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 178
- 150000003839 salts Chemical class 0.000 claims abstract description 147
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 62
- 230000000648 anti-parkinson Effects 0.000 claims abstract description 35
- 239000000939 antiparkinson agent Substances 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 230000008717 functional decline Effects 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims description 70
- 208000024891 symptom Diseases 0.000 claims description 65
- 238000011282 treatment Methods 0.000 claims description 63
- 230000008859 change Effects 0.000 claims description 60
- 230000000977 initiatory effect Effects 0.000 claims description 33
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 20
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 20
- 229960004502 levodopa Drugs 0.000 claims description 16
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 16
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical group CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 claims description 14
- 229960003946 selegiline Drugs 0.000 claims description 14
- 230000001747 exhibiting effect Effects 0.000 claims description 12
- 229960001956 rasagiline mesylate Drugs 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 7
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 6
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 6
- 229960003805 amantadine Drugs 0.000 claims description 6
- 229960001081 benzatropine Drugs 0.000 claims description 6
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 6
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 6
- 229960002802 bromocriptine Drugs 0.000 claims description 6
- 229960004596 cabergoline Drugs 0.000 claims description 6
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 6
- 229960003337 entacapone Drugs 0.000 claims description 6
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 6
- 229960003089 pramipexole Drugs 0.000 claims description 6
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 6
- 229960001879 ropinirole Drugs 0.000 claims description 6
- 229960003179 rotigotine Drugs 0.000 claims description 6
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 6
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 6
- 229960004603 tolcapone Drugs 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 29
- 201000010099 disease Diseases 0.000 abstract description 27
- 230000000051 modifying effect Effects 0.000 abstract description 16
- 229940068196 placebo Drugs 0.000 description 98
- 239000000902 placebo Substances 0.000 description 98
- 238000004458 analytical method Methods 0.000 description 61
- 230000003111 delayed effect Effects 0.000 description 35
- 230000033001 locomotion Effects 0.000 description 28
- 229940079593 drug Drugs 0.000 description 24
- 239000003814 drug Substances 0.000 description 24
- ZOMSMJKLGFBRBS-UHFFFAOYSA-N bentazone Chemical compound C1=CC=C2NS(=O)(=O)N(C(C)C)C(=O)C2=C1 ZOMSMJKLGFBRBS-UHFFFAOYSA-N 0.000 description 14
- 230000006866 deterioration Effects 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 206010044565 Tremor Diseases 0.000 description 13
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 13
- 230000001771 impaired effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 238000007405 data analysis Methods 0.000 description 10
- 230000008014 freezing Effects 0.000 description 10
- 238000007710 freezing Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 9
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000324 neuroprotective effect Effects 0.000 description 8
- QLMMOGWZCFQAPU-UHFFFAOYSA-N CGP-3466 Chemical compound C#CCN(C)CC1=CC2=CC=CC=C2OC2=CC=CC=C12 QLMMOGWZCFQAPU-UHFFFAOYSA-N 0.000 description 7
- 208000006083 Hypokinesia Diseases 0.000 description 7
- 206010034010 Parkinsonism Diseases 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 229940001133 rasagiline 1 mg Drugs 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 208000027089 Parkinsonian disease Diseases 0.000 description 6
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 6
- 239000000812 cholinergic antagonist Substances 0.000 description 6
- 230000001144 postural effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 230000005021 gait Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 206010006100 Bradykinesia Diseases 0.000 description 4
- 206010013642 Drooling Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010030312 On and off phenomenon Diseases 0.000 description 4
- 208000008630 Sialorrhea Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000008921 facial expression Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000004112 neuroprotection Effects 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 238000013179 statistical model Methods 0.000 description 4
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 3
- 208000002740 Muscle Rigidity Diseases 0.000 description 3
- 206010071390 Resting tremor Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 230000003483 hypokinetic effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000023060 memory loss Diseases 0.000 description 3
- -1 organic acid salts Chemical class 0.000 description 3
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010056696 Gaze palsy Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 244000141009 Hypericum perforatum Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229940124604 anti-psychotic medication Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 201000003083 communicating hydrocephalus Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000011979 disease modifying therapy Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940126602 investigational medicinal product Drugs 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- SQAZQLMBEHYFJA-BTJKTKAUSA-N n-(benzo[b][1]benzoxepin-5-ylmethyl)-n-methylprop-2-yn-1-amine;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C#CCN(C)CC1=CC2=CC=CC=C2OC2=CC=CC=C12 SQAZQLMBEHYFJA-BTJKTKAUSA-N 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 238000011859 neuroprotective therapy Methods 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000001975 sympathomimetic effect Effects 0.000 description 2
- 229940064707 sympathomimetics Drugs 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- PAXWQORCRCBOCU-LURJTMIESA-N 6-fluoro-L-dopa Chemical compound OC(=O)[C@@H](N)CC1=CC(O)=C(O)C=C1F PAXWQORCRCBOCU-LURJTMIESA-N 0.000 description 1
- 206010072413 Action tremor Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 208000006104 Cytochrome P-450 CYP1A2 Inhibitors Diseases 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010057333 Micrographia Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010073211 Postural tremor Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008039 Secondary Parkinson Disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 229940031774 azilect Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000021058 soft food Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13193608P | 2008-06-13 | 2008-06-13 | |
| US61/131,936 | 2008-06-13 | ||
| US18972408P | 2008-08-22 | 2008-08-22 | |
| US61/189,724 | 2008-08-22 | ||
| PCT/US2009/003528 WO2009151625A1 (en) | 2008-06-13 | 2009-06-12 | Rasagiline for parkinson's disease modification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2727022A1 true CA2727022A1 (en) | 2009-12-17 |
Family
ID=41415378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2727022A Abandoned CA2727022A1 (en) | 2008-06-13 | 2009-06-12 | Rasagiline for parkinson's disease modification |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090312436A1 (enExample) |
| EP (2) | EP2296462A4 (enExample) |
| JP (3) | JP2011522892A (enExample) |
| CN (2) | CN103893160A (enExample) |
| AU (2) | AU2009258151A1 (enExample) |
| BR (1) | BRPI0909894A2 (enExample) |
| CA (1) | CA2727022A1 (enExample) |
| EA (1) | EA201170018A1 (enExample) |
| IL (1) | IL209131A0 (enExample) |
| MX (1) | MX2010013766A (enExample) |
| NZ (1) | NZ589445A (enExample) |
| WO (1) | WO2009151625A1 (enExample) |
| ZA (1) | ZA201008484B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009032273A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| WO2009089049A1 (en) * | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| BRPI0909997A2 (pt) | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| DK2451771T3 (da) | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| WO2012015946A1 (en) * | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
| RU2587330C2 (ru) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| MX2013004598A (es) * | 2010-10-26 | 2013-07-17 | Teva Pharma | Rasagilina enriquesida con deuterio. |
| CA2732440C (en) * | 2011-02-23 | 2017-10-31 | Universite Laval | Cystamine analogues for the treatment of parkinson`s disease |
| HK1200315A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | R(+)-n-formyl-propargyl-aminoindan |
| JP2014534195A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンシトルアミド |
| HK1200314A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceuticals Usa, Inc. | R(+)-n-methyl-propargyl-aminoindan |
| US9308182B2 (en) | 2012-08-17 | 2016-04-12 | Teva Pharmaceutical Industries, Ltd. | Parenteral formulations of rasagiline |
| JP2017517481A (ja) * | 2014-04-01 | 2017-06-29 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンに対する応答を予測するために有用な一塩基多型の決定 |
| US10292947B2 (en) * | 2016-03-26 | 2019-05-21 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for N-propargylamine derivative |
| CA3058818A1 (en) * | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| JP7473565B2 (ja) * | 2019-01-28 | 2024-04-23 | ミトコンドリア エモーション， インク． | マイトフュージン活性化物質及びその使用方法 |
| GB202109826D0 (en) * | 2021-07-07 | 2021-08-18 | Bial Portela & Ca Sa | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| CN1031995C (zh) * | 1991-01-02 | 1996-06-12 | 奥韦特有限公司 | N-炔丙基-1-氨基茚满的r-对映体的制法 |
| IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69738275T2 (de) * | 1996-12-18 | 2008-08-28 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| AU2002319615A1 (en) * | 2001-07-20 | 2003-03-03 | Mount Sinai School Of Medicine Of New York University | Methods for diagnosing and treating alzheimer's disease and parkinson's disease |
| JP3878178B2 (ja) * | 2001-12-28 | 2007-02-07 | 武田薬品工業株式会社 | 排尿障害予防治療剤 |
| EP1567152B1 (en) * | 2002-11-15 | 2013-08-14 | Teva Pharmaceutical Industries Limited | Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| CA2901244A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| JP2009521402A (ja) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
| US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| RS52183B (sr) | 2006-12-14 | 2012-10-31 | Teva Pharmaceutical Industries, Ltd. | Kristalna čvrsta baza razagilina |
| BRPI0718339A2 (pt) * | 2006-12-14 | 2014-02-18 | Teva Pharma | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009032202A1 (en) * | 2007-08-29 | 2009-03-12 | Nuon Therapeutics, Inc. | Treatment of brain disorders |
| WO2009032273A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| WO2009089049A1 (en) * | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| BRPI0909997A2 (pt) * | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| AU2010304755A1 (en) * | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
-
2009
- 2009-06-12 BR BRPI0909894-1A patent/BRPI0909894A2/pt not_active IP Right Cessation
- 2009-06-12 NZ NZ589445A patent/NZ589445A/xx unknown
- 2009-06-12 CA CA2727022A patent/CA2727022A1/en not_active Abandoned
- 2009-06-12 EP EP09762921A patent/EP2296462A4/en not_active Withdrawn
- 2009-06-12 CN CN201310714021.5A patent/CN103893160A/zh active Pending
- 2009-06-12 EA EA201170018A patent/EA201170018A1/ru unknown
- 2009-06-12 WO PCT/US2009/003528 patent/WO2009151625A1/en not_active Ceased
- 2009-06-12 JP JP2011513503A patent/JP2011522892A/ja active Pending
- 2009-06-12 MX MX2010013766A patent/MX2010013766A/es not_active Application Discontinuation
- 2009-06-12 CN CN2009801230031A patent/CN102065687A/zh active Pending
- 2009-06-12 AU AU2009258151A patent/AU2009258151A1/en not_active Abandoned
- 2009-06-12 EP EP20130176166 patent/EP2666356A1/en not_active Withdrawn
- 2009-06-12 US US12/456,166 patent/US20090312436A1/en not_active Abandoned
-
2010
- 2010-11-04 IL IL209131A patent/IL209131A0/en unknown
- 2010-11-25 ZA ZA2010/08484A patent/ZA201008484B/en unknown
-
2013
- 2013-11-27 US US14/092,526 patent/US20140243418A1/en not_active Abandoned
-
2014
- 2014-12-17 JP JP2014255148A patent/JP2015096532A/ja active Pending
-
2016
- 2016-11-15 AU AU2016259315A patent/AU2016259315A1/en not_active Abandoned
- 2016-12-02 JP JP2016234976A patent/JP2017081938A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2296462A1 (en) | 2011-03-23 |
| CN102065687A (zh) | 2011-05-18 |
| JP2011522892A (ja) | 2011-08-04 |
| MX2010013766A (es) | 2011-03-15 |
| IL209131A0 (en) | 2011-01-31 |
| WO2009151625A1 (en) | 2009-12-17 |
| JP2017081938A (ja) | 2017-05-18 |
| JP2015096532A (ja) | 2015-05-21 |
| AU2009258151A1 (en) | 2009-12-17 |
| BRPI0909894A2 (pt) | 2015-07-28 |
| CN103893160A (zh) | 2014-07-02 |
| AU2016259315A1 (en) | 2016-12-01 |
| EP2296462A4 (en) | 2011-06-15 |
| NZ589445A (en) | 2013-06-28 |
| US20090312436A1 (en) | 2009-12-17 |
| EA201170018A1 (ru) | 2011-08-30 |
| ZA201008484B (en) | 2012-05-30 |
| US20140243418A1 (en) | 2014-08-28 |
| EP2666356A1 (en) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090312436A1 (en) | Rasagiline for parkinson's disease modification | |
| Schatzberg et al. | A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression | |
| Detke et al. | Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression | |
| Reimherr et al. | A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients | |
| WO2011042812A1 (en) | Use of rasagiline for the treatment of progressive supranuclear palsy | |
| TW202304461A (zh) | 自發性震顫之治療 | |
| KR20180114250A (ko) | 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법 | |
| US20220016095A1 (en) | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| KR20250034521A (ko) | 실조증을 치료하기 위한 릴루졸 전구약물의 용도 | |
| US20230270738A1 (en) | Methods of treating agitation associated with alzheimer's disease | |
| US20230372335A1 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
| CN118284412A (zh) | 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗 | |
| WO2024216061A1 (en) | Methods of treating depression and anhedonia | |
| WO2024216046A1 (en) | Methods of treating anhedonia | |
| HK1192112A (en) | Rasagiline for parkinson's disease modification | |
| Ahlskog et al. | Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa | |
| TW202333705A (zh) | 治療與阿茲海默症相關之激越的方法 | |
| TW200916091A (en) | Neramexane for the treatment of nystagmus | |
| WO2024196957A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| WO2023214314A1 (en) | Vodobatinib for reducing progression of parkinson's disease | |
| Jiang et al. | Treatment of Depression in the Medically Ill | |
| Stanković et al. | Sulpiride Augmentation in refractory depression | |
| Friedman | Neuroleptic parkinsonism | |
| Feighner et al. | Efficacy of nefazodone versus placebo in a double-blind trial of depressed inpatients | |
| Shrivastava et al. | Nefazodone vs. Sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140529 |
|
| FZDE | Discontinued |
Effective date: 20180426 |